

JULY 2025

Date	Headline and Source	Link	Summary
2 nd July	AstraZeneca India gets CDSCO nod for new Imfinzi indication to treat endometrial cancer CNBC TV18, July 02, 2025	AstraZeneca India gets CDSCO nod for new Imfinzi indication to treat endometrial cancer	AstraZeneca Pharma India Limited on Tuesday (July 1) said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import durvalumab solution for infusion (Brand name: Imfinzi) in 120 mg/2.4 ml and 500 mg/10 ml strengths for an additional indication.
8 th July	Dengue Vaccine: Experts Announce Breakthrough Patrika, July 08, 2025	Dengue Vaccine: Experts Announce Breakthrough	This vaccine is developed by the Japanese pharmaceutical company Takeda and is named TAK003 (Qdenga). Besides vaccination, significant research is underway in dengue treatment. Experts say scientists are continuously working on new treatments and medications that will not only help in faster recovery but also mitigate the effects of the disease.
9 th July	NITI Aayog Calls For Quality Overhaul In Pharma, Industry Flags Challenges News 18, July 09, 2025	NITI Aayog Calls For Quality Overhaul In Pharma, Industry Flags Challenges	With a strong network of over 3,000 pharmaceutical companies and approximately 10,500 manufacturing units across the country, it is essential to invest in and uphold the highest quality standards for pharmaceuticals, highlighted the letter sent to various industry associations, including Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers Association (IDMA), Laghu Udyog Bharati, Bulk Drug Manufacturers Association (India), Organisation of Pharmaceutical Producers of India (OPPI), Federation of Pharma Entrepreneurs (FOPE) among others.
9 th July	MSMEs raise their concerns in a discussion organised by NITI Aayog PharmaBiz, July 09, 2025	MSMEs raise their concerns in a discussion organised by NITI Aayog	Representatives of various organisations including Indian Pharmaceutical Alliance (IP Alliance), Organisation of Pharmaceutical Producers of India (OPPI), Indian Drug Manufacturers Association (IDMA), Laghu Udyog Bharati (LUB), Confederation of Indian Pharmaceutical Industry (CIPI), Federation of Pharmaceutical Entrepreneurs (FOPE), Confederation of Indian Industry (CII), and Federation of Indian Chambers of Commerce and Industry (FICCI), among others.

10 th July	Eisai Pharma: Izai Pharma GCC in Visakha Andhra Jyothy, July 10, 2025	Eisai Pharma: Izai Pharma GCC in Visakha	Makoto Hocketts, CEO of leading pharma company Isai Global, announced that they are setting up a Global Capability Center (GCC) in Visakhapatnam, and the state government is supporting it. Along with representatives of his company, he visited Geetam University on Wednesday.
11 th July	IIM Ahmedabad and Novo Nordisk India partner to combat obesity and enhance healthcare systems India Today, July 11, 2025	IIM Ahmedabad and Novo Nordisk India partner to combat obesity and enhance healthcare systems	Novo Nordisk's weight loss medication, Wegovy, has also made its debut in India, marking a significant milestone in the country's battle against obesity. Photo: Wikimedia commons On July 8, 2025, the Indian Institute of Management Ahmedabad (IIMA) and Novo Nordisk India Pvt Ltd (NNIPL) entered into a strategic collaboration aimed at enhancing the healthcare ecosystem in India.
13 th July	Obesity care project kicks off at IIM (A) The Financial Express, July 13, 2025	Obesity care project kicks off at IIM (A)	IIM-Ahmedabad and Novo Nordisk are collaborating to strengthen the healthcare ecosystem in India through a multi-dimensional approach focused on non-communicable diseases, especially obesity. This will help doctors and scientists understand diseases like cancer, diabetes, heart problems and more.
14 th July	Pfizer Gets CDSCO Panel Nod To Conduct Phase III Trial of RSV Vaccine in India, Told to Clarify Subject Criteria Medical Dialogues, July 14, 2025	Pfizer Gets CDSCO Panel Nod To Conduct Phase III Trial of RSV Vaccine in India, Told to Clarify Subject Criteria	Respiratory Syncytial Virus Prefusion F Subunit Vaccine (RSVPref) is a vaccine developed by Pfizer to prevent lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV). It is approved for use in older adults (60 years and older) and for maternal immunization to protect infants from birth through six months of age.
15 th July	AstraZeneca Pharma gets CDSCO nod to market Imfinzi for muscle-invasive bladder cancer CNBC TV18, July 15, 2025	AstraZeneca Pharma gets CDSCO nod to market Imfinzi for muscle-invasive bladder cancer	AstraZeneca Pharma gets CDSCO nod to market Imfinzi for muscle-invasive bladder cancer. The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment post radical cystectomy.
15 th July	Eisai Pharma To Set Up Global Tech Hub in Visakhapatnam Construction World, July 15, 2025	Eisai Pharma To Set Up Global Tech Hub in Visakhapatnam	Eisai Pharma, a global healthcare company, has announced plans to establish a Global Capability Centre (GCC) in Visakhapatnam, strengthening its digital innovation footprint in India. The announcement was made by Makoto Hoketsu, Global CIO of Eisai, during a visit

			to GITAM Deemed to be University on Wednesday.
15 th July	API and Eli Lilly launch nationwide CME programme to strengthen obesity care among indian physicians Express Healthcare, July 15, 2025	API and Eli Lilly launch nationwide CME programme to strengthen obesity care among indian physicians	Eli Lilly and Company (India), in partnership with the Association of Physicians of India (API), has launched a national Continuing Medical Education (CME) programme titled API – Obesity Gurukul. The initiative is designed to support physicians in developing clinical competencies to manage obesity, which has become a significant public health issue in India.
16 th July	AstraZeneca gains CDSCO approval for treatment of muscle-invasive bladder cancer Express Pharma, July 16, 2025	AstraZeneca gains CDSCO approval for treatment of muscle-invasive bladder cancer	AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO), to import and distribute Durvalumab solution for infusion for an additional indication in India. The newly approved indication allows the use of Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Durvalumab as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).
17 th July	Obesity Gurukul launched by Lilly and API to support medical education Media Brief, July 17, 2025	Obesity Gurukul launched by Lilly and API to support medical education	Eli Lilly and Company (India), in collaboration with the Association of Physicians of India (API), announces the launch of API – Obesity Gurukul, a Continuing Medical Education (CME) program aimed at enhancing physicians clinical capabilities to address obesity, which is emerging as one of India's public health challenges.
17 th July	Emcure, Sanofi enter exclusive distribution deal The Asian Age, July 17, 2025	Emcure, Sanofi enter exclusive distribution deal	Emcure Pharmaceuticals and Sanofi India (SIL) have entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India. Emcure will distribute OAD range of products that include brands like Amaryl, Cetapin.
25 th July	CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibb's Mavacamten Study Medical Dialogues, July 25, 2025	CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibb's Mavacamten Study	Bristol-Myers Squibb presented the amendment related to its Phase IV clinical study protocol titled: A Phase 4, SingleArm, OpenLabel Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy in India (ROVER) under Protocol No.

			CV0271146, Amendment 01, dated 5th February 2025.
25 th July	Lilly launches We Know Now campaign to change obesity views Afaqs, July 25, 2025	Lilly launches We Know Now campaign to change obesity views	Eli Lilly and Company (India) has announced the launch of its first-ever integrated awareness campaign, We Know Now, aimed at changing how obesity is perceived moving the conversation from blame to understanding and encouraging evidence-based care that recognises the science behind obesity, with lifestyle changes as the foundation.
28 th July	Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease Medical Dialogues, July 28, 2025	Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease	Roche has announced it has received CE Mark for its Elecsys pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer's disease. The test, which has been developed in collaboration with Eli Lilly and Company, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline.
